other_activity-27036 Article (Faculty180)

cited authors

  • Nazir, Salik; Ahuja, Kee R; Virk, Hafeez U H; Elzanaty, Ahmed; Waheed, T A; Changal, K H; Wohlfarth, Kevin; Lakhter, Vladimir; Grande, Robert D; Eltahawy, Eh A


  • Previous studies have shown similar rates of major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients, treated with P2Y inhibitors based on genotype guidance compared to standard treatment. However, given lower than expected event rates, these studies were underpowered to assess hard outcomes. We sought to systematically analyze this evidence using pooled data from multiple studies.